Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Troussard

Showing results (321-330 of 365) with videos related to

Pageof 37
Sort By:
Cancer Epidemiology|February 12, 2021
What is the most appropriate period to define synchronous cancers?Florent Baicry, Florence Molinié, Sandrine Plouvier, et al.
Leukemia|August 27, 2005
Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genesY Vasconcelos, J De Vos, L Vallat, et al.
British Journal of Haematology|April 23, 2014
Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemiaEdouard Cornet, Cécile Tomowiak, Aline Tanguy-Schmidt, et al.
British Journal of Haematology|April 24, 2024
Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study)Florence Nguyen-Khac, Marine Baron, Romain Guièze, et al.
Leukemia|January 23, 2009
Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the diseaseF Jardin, M Callanan, D Penther, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2013
Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSAA Trebouet, T Marchand, R Lemal, et al.
The Lancet. Oncology|February 2, 2024
Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based studyRoberta De Angelis, Elena Demuru, Paolo Baili, et al.
European Journal of Cancer (Oxford, England : 1990)|October 31, 2025
Skin melanoma survival is improving in Europe but regional differences persist: Results of the EUROCARE-6 studyEmanuele Crocetti, Damien Bennett, Valérie Jooste, et al.
British Journal of Haematology|November 19, 2016
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patientsAnne Wanquet, Rudy Birsen, Charlotte Bonnet, et al.
BMC Cancer|January 23, 2008
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesJoshua Z Press, Alessandro De Luca, Niki Boyd, et al.
Pageof 37

Showing results (321-330 of 365) with videos related to

Sort By:
Pageof 37
Cancer Epidemiology|February 12, 2021
What is the most appropriate period to define synchronous cancers?Florent Baicry, Florence Molinié, Sandrine Plouvier, et al.
Leukemia|August 27, 2005
Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genesY Vasconcelos, J De Vos, L Vallat, et al.
British Journal of Haematology|April 23, 2014
Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemiaEdouard Cornet, Cécile Tomowiak, Aline Tanguy-Schmidt, et al.
British Journal of Haematology|April 24, 2024
Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study)Florence Nguyen-Khac, Marine Baron, Romain Guièze, et al.
Leukemia|January 23, 2009
Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the diseaseF Jardin, M Callanan, D Penther, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2013
Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSAA Trebouet, T Marchand, R Lemal, et al.
The Lancet. Oncology|February 2, 2024
Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based studyRoberta De Angelis, Elena Demuru, Paolo Baili, et al.
European Journal of Cancer (Oxford, England : 1990)|October 31, 2025
Skin melanoma survival is improving in Europe but regional differences persist: Results of the EUROCARE-6 studyEmanuele Crocetti, Damien Bennett, Valérie Jooste, et al.
British Journal of Haematology|November 19, 2016
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patientsAnne Wanquet, Rudy Birsen, Charlotte Bonnet, et al.
BMC Cancer|January 23, 2008
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesJoshua Z Press, Alessandro De Luca, Niki Boyd, et al.
Pageof 37